Theriva Biologics, Inc.
TOVX
$0.32
-$0.02-5.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.23% | 66.60% | -201.99% | 2.77% | 42.43% |
| Total Depreciation and Amortization | -3.57% | 3.70% | 3.85% | -3.70% | -18.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.78% | -94.01% | 5,464.29% | -168.57% | -93.05% |
| Change in Net Operating Assets | -194.49% | 24.10% | -138.97% | 43.80% | -303.95% |
| Cash from Operations | 33.27% | 8.34% | 0.93% | -1.39% | -19.88% |
| Capital Expenditure | 100.00% | -18.75% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -18.75% | -- | -- | -- |
| Total Debt Issued | -55.88% | -40.35% | -95.93% | -- | -- |
| Total Debt Repaid | 50.00% | 81.82% | 80.36% | -- | -- |
| Issuance of Common Stock | 3,662.01% | -95.83% | -- | -- | -99.81% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -347.06% | -746.48% | -95.89% | -- | -- |
| Cash from Financing | 5,814.86% | -102.17% | 121.71% | 43,785.71% | -99.81% |
| Foreign Exchange rate Adjustments | 54.72% | -241.94% | -133.33% | 175.61% | -823.53% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 220.38% | -323.78% | 228.98% | 66.90% | -2,570.56% |